PHARMACOLOGY AND DRUG DEVELOPMENT

[1] AMES MM, 1988, P AM ASSOC CANC RES, V29, P196

[2] BORK E, 1988, P AM ASSOC CANC RES, V29, P229

[3] COLLINS JM, 1986, CANCER TREAT REP, V70, P73

[4] COLLINS JM, 1987, CONCEPTS CLIN DEV TH, P129

[5] PREDICTIVE MODEL FOR PLASMA CONCENTRATION-VERSUS-TIME PROFILES OF INVESTIGATIONAL ANTICANCER DRUGS IN PATIENTS [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (11) : 815 - 819

[6] EGORIN MJ, 1986, CANCER RES, V46, P1513

[7] EGORIN MJ, 1985, CANCER RES, V45, P6502

[8] EVANS WE, 1984, LANCET, V1, P359

[9] FOSTER BJ, 1988, P AN M AM SOC CLIN, V7, P64

[10] LEIBY JM, 1988, P AM ASSOC CANC RES, V29, P278

[1] AMES MM, 1988, P AM ASSOC CANC RES, V29, P196

[2] BORK E, 1988, P AM ASSOC CANC RES, V29, P229

[3] COLLINS JM, 1986, CANCER TREAT REP, V70, P73

[4] COLLINS JM, 1987, CONCEPTS CLIN DEV TH, P129

[5] PREDICTIVE MODEL FOR PLASMA CONCENTRATION-VERSUS-TIME PROFILES OF INVESTIGATIONAL ANTICANCER DRUGS IN PATIENTS [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (11) : 815 - 819

[6] EGORIN MJ, 1986, CANCER RES, V46, P1513

[7] EGORIN MJ, 1985, CANCER RES, V45, P6502

[8] EVANS WE, 1984, LANCET, V1, P359

[9] FOSTER BJ, 1988, P AN M AM SOC CLIN, V7, P64

[10] LEIBY JM, 1988, P AM ASSOC CANC RES, V29, P278